A synthetic drug that can reverse fatty liver disease, a serious metabolic condition involving an abnormal build-up of fat in the liver, which damages the organ, has been developed.

The compound known as SR9238 is the first to effectively suppress lipid or fat production in the liver, eliminating inflammation and reversing fat accumulation in animal models of fatty liver disease, the journal Chemical Biology reports.
Researchers from the Florida campus of the Scripps Research Institute (TSRI) found the new compound also significantly lowered total cholesterol levels.
"We've been working on a pair of natural proteins called LXR alpha and LXR beta that stimulate fat production in the liver, and we thought our compound might be able to successfully suppress this process," said Thomas Burris, professor at TSRI, who led the study, according to a Scripps statement.
"Once the animals were put on the drug, we were able to reverse the disease after a single month with no adverse side effects while they ate a high-fat diet," added Burris.
Burris and his colleagues designed SR9238 so that it would be quickly metabolized in the liver to minimize migration of the drug into the bloodstream, which could lead to side effects.
In addition, the scientists observed an 80 percent reduction of the enzyme responsible for producing cholesterol - the same enzyme targeted by medicines.
Source-IANS
MEDINDIA




Email










